Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_3
5
83%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
5(83.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 35 (83.3%)
Phase 41 (16.7%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

NCT03493542
completedphase_3

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

NCT02576054
completedphase_3

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

NCT01862874
completedphase_4

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

NCT01544478
completedphase_3

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

NCT00092547
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03493542Phase 3

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Completed
NCT02576054Phase 3

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Completed
NCT01862874Phase 3

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Completed
NCT01544478Phase 4

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Completed
NCT00092547Phase 3

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Completed
NCT00092521Phase 3

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6